Outlier kinase expression by RNA sequencing as targets for precision therapy

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Protein kinases are crucial therapeutic targets in cancer treatment.
• Identifying kinase aberrations is a key area in cancer genomics.
• Understanding kinase expression patterns can reveal new therapeutic strategies.

Purpose of the Study:

• To identify distinct "outlier kinases" in individual breast and pancreatic cancer samples.
• To investigate the therapeutic potential of these outlier kinases.
• To assess the utility of RNA sequencing for identifying precision therapeutic targets.

Main Methods:

• Analysis of transcriptome sequencing data from 482 cancer and benign samples across 25 tissue types.
• Definition of outlier kinases based on absolute and differential gene expression.
• Validation of outlier kinase dependencies using siRNA knockdown and pharmacologic inhibition.

Main Results:

• Distinct outlier kinases were identified in breast (e.g., ERBB2, FGFR4) and pancreatic cancers (e.g., MET, AKT2, PLK2).
• Outlier kinases demonstrated sample-specific dependencies in cell line models.
• Outlier expression of polo-like kinases in pancreatic cancer correlated with sensitivity to a pan-PLK inhibitor.

Conclusions:

• Outlier kinases represent effective, sample-specific precision therapeutic targets.
• RNA sequencing is a viable method for identifying these targets in tumors.
• Targeting outlier kinases offers a promising avenue for precision oncology.